Advertisement


Cara Norelli, MS, AGNP-C, on Managing Dermatologic Side Effects in Patients With Cancer

2024 JADPRO Live

Advertisement

Cara Norelli, MS, AGNP-C, of Memorial Sloan Kettering Cancer Center, discusses her presentation on dermatologic toxicities seen in patients with cancer from the JADPRO Live conference recently held in Grapevine, Texas. Ms. Norelli covers the importance of knowing the distinguishing characteristics among the different types of rashes or lesions often seen in patients receiving cancer treatment, identifying dermatologic emergencies, and maintaining communication with patients to properly manage dermatologic adverse events.



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
Hi everyone, my name is Cara Norelli. I am a nurse practitioner specializing in oncodermatology. I recently had the pleasure of presenting on November 16th with my colleague Purvi Desai at JADPRO Live 2024 in Grapevine, Texas. Our presentation focused on dermatologic conditions in oncology care. The skin, hair, and nails and internal malignancies are manifested in various ways and in all phases of patients experience with cancer. All cancer treatments are associated with cutaneous adverse events, this is why having a basic knowledge of oncodermatology is so important in oncology. We discussed skin adverse events such as exanthematous, lichenoid, eczematous, and acneiform drug eruptions. Did you know that there is a generally good correlation between developing an acneiform (acne-like) drug rash and positive treatment response when taking an EGFR inhibitor medication? Meaning that the appearance of the rash is often seen as a positive sign indicating the drug is effectively targeting the cancer. In our talk, we also discussed adverse events seen with the nails and hair. Lastly, we discussed dermatologic emergencies which all oncology clinicians should learn to recognize, assess, and treat. Some dermatologic emergencies are life threatening if not addressed in real time. When treating patients its important to provide hand-written instructions on safe topical and oral therapy use. Explain to your patient that your optimal goal is to better patients' physical function and quality of life, and to avoid dose reductions or discontinuation of cancer treatment.

Related Videos

Solid Tumors
Hematologic Malignancies

Justin Arnall, PharmD, BCOP, FCCP, on Complicating “Factors”: When Malignancy and Non-Malignant Hematology Collide

Justin Arnall, PharmD, BCOP, FCCP, of Atrium Health Specialty Pharmacy Service in Charlotte, North Carolina, discusses his JADPRO Live presentation on critical considerations when planning for cancer-related procedures in patients with hereditary/congenital as well as acquired bleeding disorders.

Breast Cancer

Kathryn Newlin, RN, MSN, ANP-BC, on Updates in HR-Positive, HER2-Negative Metastatic Breast Cancer

Kathryn Newlin, RN, MSN, ANP-BC, of Washington University in St. Louis, discusses her presentation on HR+ HER2- metastatic breast cancer from the JADPRO Live conference recently held in Grapevine, Texas. Kathryn covers factors involved in treatment selection for this patient population, including key agents in the armamentarium, relevant biomarkers and the emergence of HER2 low as a factor in added treatment options, and the management of adverse effects.  

Advertisement

Advertisement




Advertisement